FDA board votes to approve gene therapy for Duchenne muscular dystrophy
In the Pipeline: Gene Therapy - Sarepta Therapeutics
Duchenne Muscular Dystrophy (DMD): Gene Therapy and Families
Sarepta Soars on Expanded Approval for Muscular Dystrophy Drug
Duchenne & Gene Therapy
In the Pipeline: Restoring Dystrophin - Sarepta Therapeutics (RNA Targeted Therapies)
Sarepta shares tumble as concerns mount over FDA approval on gene therapy
[Webinar] Introducing PPMO – Sarepta Therapeutics – May 2018
Duchenne Muscular Dystrophy: Could Gene Therapy Be the Answer? Exploring SRP-9001
Gene therapy trial in muscular dystrophy patients shows exciting results
Gene therapy for Duchenne muscular dystrophy gets FDA approval
Groundbreaking Gene Therapy for Duchenne Muscular Dystrophy | Nemours Children’s Health
Updates in Safety and Efficacy of Gene Therapy for DMD
Webinar: SRP-9001 Gene Therapy Path Forward (November 2020)
Sarepta working on groundbreaking gene therapies in central Ohio
Mechanism of Action of SRP-9001, A Gene Therapy For Duchenne Muscular Dystrophy
Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
FDA Approves First Gene Therapy for Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD): Gene Therapy and How Muscle Responds
How Does Gene Therapy Work for Patients with Duchenne Muscular Dystrophy?
